GlassScriptPhysician profile
Samuel A Nussbaumer
NPI 1073515508
$16,377.27
in general payments reported to CMS, 2019-2025
36 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $152 · 2021: $652 · 2022: $1,256 · 2023: $1,185 · 2024: $1,640 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611 · Travel and Lodging: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.98 |
| Travel and Lodging | $627.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $9,472.93 | 2019 | |
| Boston Scientific Corporation | $1,229.29 | 2019-2024 | Jetstream Sc, Eluvia, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $803.38 | 2019-2024 | Jot Dx, Assurity, Xience Sierra |
| Abiomed | $502.94 | 2021-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $430.97 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $404.52 | 2019-2025 | |
| Amgen INC. | $390.70 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $337.70 | 2022-2025 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $315.13 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $314.70 | 2020-2025 | Lifevest |
| Pfizer INC. | $247.69 | 2022-2024 | |
| Esperion Therapeutics, INC. | $245.95 | 2021-2023 | Nexletol |
| Astellas Pharma US INC | $226.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $221.05 | 2019-2022 | |
| Amarin Pharma, INC. | $210.84 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.03 | 2019-2024 | Jardiance |
| Lundbeck LLC | $107.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.83 | 2020-2023 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $80.07 | 2022-2023 | Arcalyst |
| Cvrx, INC. | $76.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $69.20 | 2019 | |
| Daiichi Sankyo INC. | $55.92 | 2022-2023 | Injectafer |
| Medtronic, INC. | $50.97 | 2022-2025 | Symplicity G3 |
| Novo Nordisk INC | $45.42 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $45.10 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $32.44 | 2019 | |
| Terumo Medical Corporation | $24.59 | 2023 | Glidewire, Angio-Seal, Glidesheath Slender |
| Philips North America LLC | $23.83 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.50 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $18.14 | 2025 | Inspire |
| Recor Medical INC | $17.39 | 2025 | Paradise Ultrasound Renal Denervation System |
| Gilead Sciences, INC. | $16.99 | 2019 | |
| Medicomp INC | $16.45 | 2023 | Telepatch Cardiac Monitor |
| Scpharmaceuticals INC. | $14.19 | 2023 | |
| Edwards Lifesciences Corporation | $14.01 | 2019 | |
| Tactile Systems Technology INC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Nussbaumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.